Mymetics Corporation (MYMX) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in Epalinges, Switzerland. The current CEO is Ronald Kempers.
MYMX has IPO date of 1999-10-26, 2 full-time employees, listed on the Other OTC, a market capitalization of $46.00.
Mymetics Corporation, a vaccine company, engages in the research and development of vaccines for infectious and life disabling diseases in Switzerland. The company's product pipeline includes various vaccine candidates, such as HIV-1/AIDS, Covid-19, intra nasal influenza, respiratory syncytial virus, malaria, and chikungunya. Mymetics Corporation has a collaboration agreement with Texas Biomedical Research Institute; PATH Malaria Vaccine Initiative and the Laboratory of Malaria Immunology and Vaccinology of the National Institute of Allergy and Infectious Diseases to develop and produce virosome based vaccine formulations for a malaria transmission-blocking vaccine candidate; and Sanofi Pasteur Biologics, LLC to investigate the immunogenicity of influenza vaccines. The company was formerly known as ICHOR Corporation and changed its name to Mymetics Corporation in July 2001. Mymetics Corporation was founded in 1990 and is based in Epalinges, Switzerland.
